Top

Published in:

Open Access 01-12-2017 | Research article

Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy

Published in: BMC Ophthalmology | Issue 1/2017

Abstract

Background

To evaluate the macular sensitivity changes after half-dose photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSCR).

Methods

Eighteen patients (26 eyes) with chronic CSCR were recruited in the same hospital between April 2011 and December 2012. All patients were treated with one session of half-dose PDT after complete ophthalmic examination. Macular sensitivity examination was performed at baseline and 1, 3 and 6 months post-treatment. Mean sensitivity (MS) of the central 10 degrees (10°) and 4 degrees (4°), mean deviation (MD) and pattern standard deviation (PSD) on automated static perimetry (Humphrey Field Analyzer II-750) were used for analysis.

Results

There was significant improvement of the 10°MS from baseline (29.76 ± 1.51 dB) to 1 month (31.74 ± 1.56 dB), 3 months (31.51 ± 1.38 dB) and 6 months (31.19 ± 1.61 dB) after treatment (P < 0.001). The 4°MS was also significantly improved with half-dose PDT from baseline (28.96 ± 1.78 dB) to 1 month (32.41 ± 1.66 dB), 3 months (32.46 ± 1.50 dB) and 6 months (31.90 ± 1.84 dB) post-treatment (P < 0.001). MD was improved from baseline (−3.39 ± 0.89 dB) to 1 month (−1.96 ± 0.29 dB), 3 months (−1.94 ± 0.29 dB) and 6 months (−2.45 ± 0.13) post-treatment (P = 0.004). PSD also improved from 1.97 ± 0.24 dB at baseline to 1.47 ± 0.27 dB, 1.34 ± 0.24 dB, and 1.53 ± 0.24 dB (P = 0.001) at 1, 3 and 6 months after treatment, respectively.

Conclusion

Macular sensitivity in CSCR can be improved by half-dose PDT, along with improvement of visual acuity and retinal thickness. The treatment outcome at 1 month may be a predictor of the final treatment response.

Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–26. doi:10.1016/j.survophthal.2012.07.004.CrossRefPubMedPubMedCentral

Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22(1):19–24.CrossRefPubMed

Baran NV, Gurlu VP, Esgin H. Long-term macular function in eyes with central serous chorioretinopathy. Clin Experiment Ophthalmol. 2005;33(4):369–72. doi:10.1111/j.1442-9071.2005.01027.x.CrossRefPubMed

Folk JC, Thompson HS, Han DP, Brown CK. Visual function abnormalities in central serous retinopathy. Arch Ophthalmol. 1984;102(9):1299–302.CrossRefPubMed

Maaranen TH, Tuppurainen KT, Mantyjarvi MI. Color vision defects after central serous chorioretinopathy. Retina. 2000;20(6):633–7.CrossRefPubMed

Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M. One-year outcomes with half-dose Verteporfin photodynamic therapy for chronic central serous Chorioretinopathy. Ophthalmology. 2014; doi:10.1016/j.ophtha.2014.09.034.

Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Mizota A, Yuzawa M. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy. Retina. 2014;34(5):964–70. doi:10.1097/iae.0000000000000027.CrossRefPubMed

Nicolo M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014;157(5):1033–7. doi:10.1016/j.ajo.2014.01.022.CrossRefPubMed

Modi RR, Butola S, Behera UC. Half-fluence versus half-dose photodynamic therapy in chronic central serous Chorioretinopathy. Am J Ophthalmol. 2015;159(1):205. doi:10.1016/j.ajo.2014.09.038.CrossRefPubMed

10.

Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y, Zhou P, Pan C, Zhang L, Liu P, Zhou H, Jiao X, Xiong Y, Tian R, Lu Y, Yu X, Li X. A 50% vs 30% dose of Verteporfin (photodynamic therapy) for acute central serous Chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015; doi:10.1001/jamaophthalmol.2014.5312.

11.

Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115(10):1756–65. doi:10.1016/j.ophtha.2008.04.014.CrossRefPubMed

12.

Husain D, Kramer M, Kenny A, Michaud N, Flotte T, Gragoudas E, Miller J. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40(10):2322–31.PubMed

13.

Tarantola RM, Law JC, Recchia FM, Sternberg P Jr, Agarwal A. Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy. Lasers Surg Med. 2008;40(10):671–5. doi:10.1002/lsm.20720.CrossRefPubMed

14.

Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye. 2010;24(12):1743–56. doi:10.1038/eye.2010.130.CrossRefPubMed

15.

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (1999). Archives of ophthalmology 117 (10):1329–1345.

16.

Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23(6):752–63.CrossRefPubMed

17.

Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87(12):1453–8.CrossRefPubMedPubMedCentral

18.

Lai TY, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol. 2004;137(5):826–33. doi:10.1016/j.ajo.2003.11.079.CrossRefPubMed

19.

Tzekov R, Lin T, Zhang KM, Jackson B, Oyejide A, Orilla W, Kulkarni AD, Kuppermann BD, Wheeler L, Burke J. Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci. 2006;47(1):377–85. doi:10.1167/iovs.05-0838.CrossRefPubMed

20.

Kim KS, Lee WK, Lee SB. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am J Ophthalmol. 2014;157(2):366–373 e361. doi:10.1016/j.ajo.2013.10.013.CrossRefPubMed

21.

Eandi CM, Piccolino FC, Alovisi C, Tridico F, Giacomello D, Grignolo FM. Correlation between fundus autofluorescence and central visual function in chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;159(4):652–8. doi:10.1016/j.ajo.2014.12.023.CrossRefPubMed

22.

Ozdemir H, Senturk F, Karacorlu M, Arf Karacorlu S, Uysal O. Macular sensitivity in eyes with central serous chorioretinopathy. Eur J Ophthalmol. 2008;18(5):799–804.PubMed

23.

Sanguansak T, Pitujaturont P, Yospaiboon Y, Sinawat S, Ratanapakorn T, Bhoomibunchoo C. Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy. Clin Ophthalmol. 2015;9:2257–61. doi:10.2147/opth.s95748.PubMedPubMedCentral

24.

Fujita K, Shinoda K, Imamura Y, Matsumoto CS, Mizutani Y, Mizota A, Yuzawa M. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy. Am J Ophthalmol. 2012;154(3):579–85. doi:10.1016/j.ajo.2012.03.043.CrossRefPubMed

25.

Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol. 2011;151(2):303–309 e301. doi:10.1016/j.ajo.2010.08.019.CrossRefPubMed

26.

Fujita K, Yuzawa M, Mori R. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Retina. 2011;31(4):772–8. doi:10.1097/IAE.0b013e3181f049d3.CrossRefPubMed

27.

Springer C, Bultmann S, Volcker HE, Rohrschneider K. Fundus perimetry with the micro perimeter 1 in normal individuals: comparison with conventional threshold perimetry. Ophthalmology. 2005;112(5):848–54. doi:10.1016/j.ophtha.2004.11.051.CrossRefPubMed

28.

Lima VC, Prata TS, De Moraes CG, Kim J, Seiple W, Rosen RB, Liebmann JM, Ritch R. A comparison between microperimetry and standard achromatic perimetry of the central visual field in eyes with glaucomatous paracentral visual-field defects. Br J Ophthalmol. 2010;94(1):64–7. doi:10.1136/bjo.2009.159772.CrossRefPubMed

29.

Midena E, Radin PP, Convento E, Cavarzeran F. Macular automatic fundus perimetry threshold versus standard perimetry threshold. Eur J Ophthalmol. 2007;17(1):63–8.PubMed

30.

Squirrell DM, Mawer NP, Mody CH, Brand CS. Visual outcome after intravitreal ranibizumab for wet age-related macular degeneration: a comparison between best-corrected visual acuity and microperimetry. Retina. 2010;30(3):436–42. doi:10.1097/IAE.0b013e3181bd2f29.CrossRefPubMed

31.

Frennesson C, Nilsson UL, Peebo BB, Nilsson SE. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Acta Ophthalmol. 2010;88(4):420–5. doi:10.1111/j.1755-3768.2009.01576.x.CrossRefPubMed

32.

Acton JH, Gibson JM, Cubbidge RP. Quantification of visual field loss in age-related macular degeneration. PLoS One. 2012;7(6):e39944. doi:10.1371/journal.pone.0039944.CrossRefPubMedPubMedCentral

33.

Sekine A, Imasawa M, Iijima H. Retinal thickness and perimetric sensitivity in central serous chorioretinopathy. Jpn J Ophthalmol. 2010;54(6):578–83. doi:10.1007/s10384-010-0869-y.CrossRefPubMed

34.

Ehrlich R, Mawer NP, Mody CH, Brand CS, Squirrell D. Visual function following photodynamic therapy for central serous chorioretinopathy: a comparison of automated macular microperimetry versus best-corrected visual acuity. Clin Exp Rheumatol. 2012;40(1):e32–9. doi:10.1111/j.1442-9071.2011.02654.x.

35.

Piccolino FC, de la Longrais RR, Ravera G, Eandi CM, Ventre L, Abdollahi A, Manea M. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol. 2005;139(1):87–99. doi:10.1016/j.ajo.2004.08.037.CrossRefPubMed

Title: Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
Publication date: 01-12-2017
Published in: BMC Ophthalmology / Issue 1/2017
Electronic ISSN: 1471-2415
DOI: https://doi.org/10.1186/s12886-017-0535-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

MiRNAs regulate oxidative stress related genes via binding to the 3′ UTR and TATA-box regions: a new hypothesis for cataract pathogenesis

Α molecular epidemiological analysis of adenoviruses from excess conjunctivitis cases

The impact of glaucoma on quality of life in Ethiopia: a case-control study

Analysis of novel Sjogren’s syndrome autoantibodies in patients with dry eyes

Hydrophilic intraocular lens opacification after posterior lamellar keratoplasty - a material analysis with special reference to optical quality assessment

Public awareness of common eye diseases in Jordan